Clinical Trials Browser

Lymphoma, Mantle-Cell

Neoplasms, Recurrence, Lymphoma, B-Cell

Lymphoma, Non-Hodgkin

Lymphoma, Non-Hodgkin

Lymphoma, Large B-Cell, Diffuse

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Dendritic Cell Sarcoma, Interdigitating

Lymphoma, Non-Hodgkin

Dendritic Cell Sarcoma, Interdigitating

Lymphoma, B-Cell

Recurrence, Lymphoma, Mantle-Cell

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Mantle-Cell

Lymphoma, Mantle-Cell

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

Lymphoma, B-Cell

Lymphoma, Mantle-Cell

Lymphoma, B-Cell

Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, Mantle-Cell

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Mantle-Cell

Aggression, Lymphoma, Non-Hodgkin, Recurrence

Recurrence, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Large B-Cell, Diffuse

Lymphoma, B-Cell

Lymphoma, Mantle-Cell

Clinical Trials

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

iMATRIX GLO

GlofitReal

GLOBRYTE

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Glofitamab in Chinese Patients With R/R DLBCL

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

CAR-T Followed by Bispecific Antibodies

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

GLOASIS

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

JASPIS-01

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

GRAIL

GLOFTST

GOlDiLOX